Wyeth discontinues Suprax
Executive Summary
Wyeth will continue to sell oral antimicrobial Suprax (cefixime) suspension through March or until company's supply is depleted, following decision to discontinue the product. Cefixime lost patent protection on Nov. 10; Wyeth said it had always intended to cease marketing the drug once it lost exclusivity...
You may also be interested in...
Suprax returning to market
The cephalosporin antibiotic Suprax (cefixime) is returning to the market after a one-year absence. The Bombay-based generic drug firm Lupin is taking over the product from Wyeth, which discontinued production in 2002 (1"The Pink Sheet" Dec. 2, 2002, In Brief); stock was exhausted in 2003. Lupin expects to have the oral suspension formulation available in April following the approval of its ANDA (65-129) on Feb. 23. The company is not projecting availability for the tablets (ANDA 65-130), approved Feb. 12. Suprax will be Lupin's first U.S. product and will be detailed by 45 sales reps calling primarily on pediatricians. Sales of Suprax during Wyeth's last year of production were approximately $50 mil...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.